SUMMIT was an open-label, international phase 2 ‘basket’ trial investigating the activity and safety of neratinib across a broad spectrum of cancers in patients whose tumours harbour activating somatic HER2 mutations25. The gene discussed is ERBB2; the disease is cancer.